Profile Previews

Get a glimpse into our company and investor data—powered by the PitchBook Platform

NeoProteomics

NeoProteomics?uq=UG6efJS6
2006 FOUNDED
PRIVATE STATUS
1-10 EMPLOYEES
Grant LATEST DEAL TYPE
$300K LATEST DEAL AMOUNT
4 INVESTORS
Description

Provider of research services and tools intended to help clients unravel the complexities of pharmaceutical and biological research. The company's research services and tools include mass spectrometry and network biology with a special interest in cancer and neural degeneration, enabling partner companies and research laboratories to get analysis tools for predicting the biological bases of diseases.

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Other Pharmaceuticals and Biotechnology
Other Industries
Other Healthcare Technology Systems
Primary Office
  • 11000 Euclid Avenue
  • Cleveland, OH 44106
  • United States
Request full access to PitchBook

You’re viewing a free company profile from the PitchBook Platform. To explore NeoProteomics’s full profile, request a free trial.

NeoProteomics Valuation and Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
3. Grant 03-Aug-2011 $300K Completed Generating Revenue
2. Accelerator/Incubator 25-Mar-2011 Completed Generating Revenue
1. Grant 11-Sep-2009 $25K Completed Startup
To view this company’s complete deal history including valuation and funding, request access »

NeoProteomics Investors (4)

Investor Name Investor Type Holding Investor Since Participating Rounds Board
Seat
Contact
Info
U.S. Department of Health and Human Services Government 000 0000 000000 0
Great Lakes Innovation and Development Enterprise Accelerator/Incubator Minority 000 0000 000000 0
Innovation Fund of Northeast Ohio Accelerator/Incubator Minority 000 0000 000000 0
Lorain County Community College Foundation Not-For-Profit Venture Capital 000 0000 000000 0

NeoProteomics Executive Team (3)

Name Title Board
Seat
Contact
Info
John Schenkel Jr. Co-Founder, President & Chief Executive Officer
Mark Chance Ph.D Co-Founder & Chief Scientific Officer
Steven Chance Secretary & General Counsel